Quince Therapeutics, Inc. (NasdaqGS:QNCX) announced that it has retained MTS Health Partners, L.P. as its financial advisor to support Quince's Board of Directors and management team in the review and evaluation of strategic alternatives intended to maximize long-term value for all Quince stockholders. The engagement will focus on the company's previously stated prioritization of in-licensing and acquisition activities, as well as alternative options and proposals, as warranted.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.75 USD | +4.87% |
|
+7.14% | -28.57% |
06-26 | Transcript : Quince Therapeutics, Inc. - Special Call | |
06-25 | Quince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.57% | 32.41M | |
+19.41% | 45.51B | |
+38.65% | 38.13B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- QNCX Stock
- News Quince Therapeutics, Inc.
- Quince Therapeutics Engages MTS Heath Partners to Review Strategic Alternatives